$203.18
1.45%
Nasdaq, Nov 28, 10:00 pm CET

Ligand Pharmaceuticals Incorporated Stock price

$203.18
+14.31 7.58% 1M
+102.99 102.79% 6M
+96.03 89.62% YTD
+80.63 65.79% 1Y
+131.53 183.57% 3Y
+151.73 294.88% 5Y
+137.88 211.13% 10Y
+173.83 592.16% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-2.98 1.45%

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.8b
Net debt
positive
Cash
$664.5m
Shares outstanding
19.7m
Valuation (TTM | estimate)
P/E
86.5 | 29.0
P/S
15.9 | 18.3
EV/Sales
15.1 | 17.3
EV/FCF
122.9
P/B
4.2
Financial Health
Equity Ratio
88.2%
Return on Equity
-0.5%
ROCE
2.0%
ROIC
2.8%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$251.2m | $219.0m
EBITDA
$61.7m | $81.2m
EBIT
$28.8m | $31.3m
Net Income
$48.6m | $137.7m
Free Cash Flow
$30.8m
Growth (TTM | estimate)
Revenue
64.8% | 31.0%
EBITDA
21.9% | 45.1%
EBIT
64.0% | 35.9%
Net Income
7.9% | 3,516.1%
Free Cash Flow
24.1%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
24.6% | 37.1%
EBIT
11.5%
Net
19.3% | 62.9%
Free Cash Flow
12.2%
More
EPS
$2.4
FCF per Share
$1.6
Short interest
6.4%
Employees
68
Rev per Employee
$2.5m
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
92%
Hold
8%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
251 251
65% 65%
100%
- Direct Costs 14 14
46% 46%
6%
237 237
66% 66%
94%
- Selling and Administrative Expenses 93 93
34% 34%
37%
- Research and Development Expense 82 82
265% 265%
33%
62 62
22% 22%
25%
- Depreciation and Amortization 33 33
1% 1%
13%
EBIT (Operating Income) EBIT 29 29
64% 64%
11%
Net Profit 49 49
8% 8%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Negative
The Motley Fool
12 days ago
Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable assets under management at quarter-end.
Positive
Seeking Alpha
16 days ago
Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a key driver of its outperformance and future investment appeal. This article evaluates LGND's ongoing investment prospects in light of its recent substantial price appreciation.
Neutral
Seeking Alpha
21 days ago
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Ca...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today